Masimo Corp Stock Price, News & Analysis

HARMAN International, a Samsung Electronics subsidiary, has completed the acquisition of Sound United from Masimo Corporation (NASDAQ: MASI). The acquisition integrates Sound United's premium audio brands including Bowers & Wilkins, Denon, Marantz, Definitive Technology, Polk Audio, HEOS, Classé, and Boston Acoustics into HARMAN's portfolio.

Sound United will operate as a standalone Strategic Business Unit (SBU) within HARMAN's Lifestyle Division, preserving each brand's heritage while leveraging HARMAN's global resources. The strategic integration aims to expand HARMAN's core audio business across key product categories including home audio, electronics, headphones, and car audio, positioning HARMAN as a comprehensive audio industry leader.

Masimo (NASDAQ: MASI) announced significant findings from a Dartmouth-Hitchcock Medical Center study showing that continuous patient monitoring using Masimo SET® and Patient SafetyNet™ technologies not only improves patient outcomes but also generates substantial cost savings.

The study, analyzing 31,993 patients over 3.5 years, revealed that avoiding patient rescue events saved approximately $5,500 per patient, while preventing transfer events saved about $10,700 per patient. For a 200-bed facility using Masimo monitoring, each 10% reduction in rescues and transfers projected annual savings of $350,000 and $409,000 respectively.

The research demonstrated that 92.7% of monitored patients had uncomplicated stays, generating an average operating gain of $2,016 per patient, while complicated cases resulted in significant losses.

Masimo (NASDAQ: MASI) has announced a significant multi-year renewal and expansion of its strategic partnership with Royal Philips (NYSE: PHG) through 2026 and beyond. The expanded collaboration will accelerate the integration of Masimo's monitoring technologies, including SET® pulse oximetry, into Philips' multi-parameter patient monitors.

The partnership includes integration of Radius PPG® with Masimo-board equipped Philips monitors and the development of next-generation wearable solutions. The companies will jointly develop and promote AI-based monitoring technologies. Additional Masimo technologies available on Philips devices include SpHb®, O3® regional oximetry, SedLine® brain function monitoring, and NomoLine® capnography.

Masimo (NASDAQ: MASI) announced its participation in the upcoming Wells Fargo Healthcare Conference. The company's management will present on Thursday, September 4, 2025, at 1:30 p.m. Eastern time. Investors can access the presentation through a live webcast on Masimo's website, with a replay available after the event.

Masimo (NASDAQ: MASI) has received FDA 510(k) clearance for expanded indications of its O3® Regional Oximetry's delta hemoglobin parameters (ΔcHb, ΔHHb, and ΔO2Hb). The expanded clearance now covers both cerebral and somatic applications across all patient populations, including pediatric and neonatal patients.

The O3 system, available on Masimo's Root® platform, uses near-infrared spectroscopy (NIRS) to monitor regional oxygen saturation (rSO2). The delta hemoglobin parameters provide crucial insights into why a patient's rSO2 is changing by tracking changes in total hemoglobin, deoxygenated hemoglobin, and oxygenated hemoglobin. Clinical studies, including a 2024 randomized controlled trial, have demonstrated improved maintenance of cerebral physiology in elderly patients using these parameters.

The technology offers both trending and absolute accuracy specifications, with ARMS accuracy of 4% for cerebral monitoring in adults and 5% for pediatric cerebral and adult non-cerebral applications.

Masimo (Nasdaq: MASI) reported strong Q2 2025 financial results, with GAAP revenue reaching $371 million, up 8% year-over-year. The company achieved non-GAAP earnings per diluted share of $1.33, representing a 46% increase from the previous year.

CEO Katie Szyman highlighted the company's successful tariff mitigation efforts, reducing the expected impact by 50%. For 2025, Masimo updated its guidance to include non-GAAP revenue of $1,505-$1,535 million, projecting 8-11% growth. The company revised its non-GAAP EPS guidance to $5.20-$5.45 including tariff impacts, down from $5.45-$5.70 before tariffs.

Masimo (NASDAQ: MASI) has scheduled its second quarter 2025 financial results announcement for Tuesday, August 5, 2025, after market close. The company will host a conference call at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results for the period ended June 28, 2025.

The conference call will be led by CEO Katie Szyman and CFO Micah Young. Participants must register in advance to receive dial-in details and a registrant ID. A replay of the webcast and conference call will be available on Masimo's website after the event.

Masimo (NASDAQ: MASI), a medical technology company specializing in noninvasive monitoring solutions, has joined the American Heart Association Center for Health Technology & Innovation's Innovators' Network. This strategic collaboration provides Masimo access to the Association's digital evidence-based guidelines and clinical recommendations for healthcare technology development.

The Innovators' Network connects entrepreneurs, providers, researchers, and payers, facilitating the development of clinical outcome studies and evidence-based healthcare technologies. Members can leverage the consortium to validate that their digital platforms improve healthcare outcomes, a crucial factor for providers and payers.

A clinical trial published in JAMA Pediatrics demonstrates significant benefits of Masimo SedLine Brain Function Monitoring in pediatric anesthesia. The study showed that EEG-guided anesthesia using SedLine reduced sevoflurane exposure by 1.4 MAC hours and decreased pediatric anesthesia emergence delirium (PAED) incidence by 14%. Patients monitored with SedLine regained consciousness 53% faster and were discharged from post-anesthesia care 48% sooner, resulting in cost savings of $240-$920 per patient. The randomized trial, conducted at Japan's largest children's hospital, involved 177 children aged 1-6 years undergoing elective surgery. The technology demonstrated improved safety, efficiency, and cost-effectiveness in pediatric anesthesia management compared to standard practice.